P&G’s Deal with ChromaDex

ChromaDex Corp., which makes proprietary health, wellness and nutritional ingredients, has entered into a joint development agreement with The Procter & Gamble Company in which it will provide P&G exclusivity to its new proprietary ingredient for use in P&G branded products.
 
ChromaDex’s portfolio includes Niagen nicotinamide riboside, billed as the first and only commercially available form of nicotinamide riboside (NR), a highly effective NAD+ booster and “no flush” form of vitamin B3 (niacin). According to reports, the accord stipulates that ChromaDex will become an exclusive supplier to P&G if stable forms of Niagen can be developed.
 
In August, ChromaDex Corp. announced results of the first controlled human clinical study on the use of the Niagen nicotinamide riboside (NR) at 4^thFederation of American Societies for Experimental Biology (FASEB) Science Research Conference on NAD+ Metabolism and Signaling.
 
Charles Brenner, PhD, who is part of the ChromaDex Scientific Advisory Board ,presented an oral platform talk on “How Nicotinamide Riboside Promotes Weight Loss.” In addition, Dr. Brenner, Frank Jaksch, Dr. Ryan Dellinger, and their co-workers presented a poster entitled, “Dose-Dependent Elevation of the Blood NAD Metabolome by NR in Healthy Human Beings.” The oral presentation and poster presented data which indicate that single doses of NIAGEN NR can elevate the co-enzyme NAD+ in the blood by as much as 2.7-fold.
 
Niagen is supported by five patents issued and several pending, with patent rights acquired from Dartmouth College, Cornell University and Washington University, according to ChromaDex.

P&G will make an undisclosed up-front payment to ChromaDex as well as other payments based on achievement of various milestones, according to ChromaDex.
 
“The joint development agreement with P&G is a significant milestone in the commercialization of our leading breakthrough ingredient,” said Frank Jaksch Jr., founder and CEO of ChromaDex. “Procter and Gamble is a market leader in consumer products and this collaboration provides ChromaDex, as an innovator of novel ingredients, an efficient way to expand into new product categories and channels.”
 
According to Jaksch, the agreement positions the new ingredient “to be included in a number of P&G products, some of which are among the highest volume consumer products in the world. Working with P&G over the past year on a series of assessments has provided for an excellent foundation for this exclusive joint development collaboration.”